Sunday, August 31, 2008

Repair Stem Cell Institute Says Stanford University's Stem Cell Study Confirms The Futility Of Embryonics In Human Therapy
The Repair Stem Cell Institute LLC (RSCI; http://www.RepairStemCells.org) reported that Stanford University School of Medicine's recent discovery there may be limitations to the effectiveness of human therapies derived from embryonic stem cells (ESC) because the cells injected in mice stimulated the kind of immune rejection seen with transplanted organs clearly delivers a blow to proponents of embryonic stem cell research who continue to ballyhoo the promise of ESC when in effect, as the Stanford study showed, the transplanted stem cells were dead within about seven to 10 days.

Repair Stem Cell Institute Says Stanford University's Stem Cell Study Confirms The Futility Of Embryonics In Human Therapy

Main Category: Stem Cell Research
Article Date: 29 Aug 2008 - 3:00 PDT

The Repair Stem Cell Institute LLC (RSCI; http://www.RepairStemCells.org) reported that Stanford University School of Medicine's recent discovery there may be limitations to the effectiveness of human therapies derived from embryonic stem cells (ESC) because the cells injected in mice stimulated the kind of immune rejection seen with transplanted organs clearly delivers a blow to proponents of embryonic stem cell research who continue to ballyhoo the promise of ESC when in effect, as the Stanford study showed, the transplanted stem cells were dead within about seven to 10 days.

According to Don Margolis, founder and chairman of the RSCI, "The new Stanford findings further confirm the futility of embryonics in human therapy despite what proponents of human ESC research have been promising, that transplanted ESC can mature into several different types of tissue. Those cells could not survive in the mouse, suggesting the same would likely occur in a patient." He noted a statement from Stanford radiologist Dr. Joseph Wu, part of the research team: "I think there's some promise [to human ESCs] but you don't want to be foolish and say these cells are going to cure things in the next five years."

Mr. Margolis said in addition to the Stanford findings presenting difficulties to one day permit human trials, the U.S. Food and Drug Administration has not approved "the injection of ESCs into patients because they also have the potential to become cancerous."

He also said, "With over 100 diseases already being treated with Repair Stem Cells by the world's finest doctors, the need for further ESC research merely to add to 10 years of futility is called into question."

Visit http://www.RepairStemCells.org/StemCellTreatmentCenters.php for RSCI's global listing of stem cell treatment centers and the practitioners meeting its standards of excellence who are already treating those 100+ medical conditions with success.

About the RSCI

The Repair Stem Cell Institute LLC is a global independent public service company dedicated to bringing the news about Repair Stem Cell treatments to the public. The RSCI was founded in April 2008 and is based in Bangkok with administrative headquarters in Dallas and a communications, government and public affairs office in Washington.

The Repair Stem Cell Institute LLC
http://www.RepairStemCells.org


http://www.medicalnewstoday.com/articles/119614.php

UT Southwestern Researchers Find Antidepressants Need New Nerve Cells To Be Effective

- NIH scientists find a novel mechanism that controls the ...
What they discovered was that mice without furin in these cells developed systemic autoimmune disease. This means that the immune systems of the mice ...

Tysabri

Elan reports narrower losses
Athlone Advertiser - Westmeath,Ireland
This comes following news earlier this week that two European patients who recently developed a dangerous brain infection after taking Tysabri are now ...
See all stories on this topic

FDA Advises Healthcare Providers on Tysabri Risk
FDA news (subscription) - Falls Church,VA,USA
Prescribing information for Tysabri (natalizumab) will be revised to include information telling prescribers and patients that cases of PML have occurred in ...
See all stories on this topic

She's on the run to help find a cure for MS
Miami Herald Fri, 29 Aug 2008 1:58 PM PDT
Eileen Friedman, 46 Plantation MS diagnosis: I was diagnosed with multiple sclerosis in 2000 after a head-on accident that totalled my car. I probably had MS 12 years prior because the symptoms came and went like a toothache. The pain in my head was intense, but I thought it was related to the accident. My brother has MS, so I went to see his neurologist.


UT Southwestern Researchers Find Antidepressants Need New Nerve Cells To Be Effective
Researchers at UT Southwestern Medical Center have discovered in mice that the brain must create new nerve cells for either exercise or antidepressants to reduce depression-like behavior.In addition, the researchers found that antidepressants and exercise use the same biochemical pathway to exert their effects.

Bioengineered Drugs Heal, but at a Big Cost
RedOrbit - Dallas,TX,USA
Since the drug was approved for use in 1998, other bioengineered drugs for rheumatoid arthritis, multiple sclerosis, cancer and other diseases have come to ...
See all stories on this topic

New PML Cases Reported With Tysabri Monotherapy
By Shirley(MDhealthChannel.com)
August 26, 2008 — Two new cases of progressive multifocal leukoencephalopathy (PML) have been reported in European multiple sclerosis patients receiving natalizumab (Tysabri, Biogen Idec, Inc), the US Food and Drug Administration (FDA) ...
- http://ms-news-channel-3.blogspot.com/



Distinguishing A Bad Mood From Depression In Teenagers, From The Harvard Mental Health Letter
The teenage years are a time of emotional highs and lows. So how do you distinguish normal teenage mood swings and rebellion from actual depression? The September 2008 issue of the Harvard Mental Health Letter highlights some ways to tell.

Even Without Dementia, Mental Skills Decline Years Before Death
A new study shows that older people's mental skills start declining years before death, even if they don't have dementia. The study is published in the August 27, 2008, online issue of Neurology®, the medical journal of the American Academy of Neurology.

Demonstration Of Subliminal Learning In The Human Brain
Although the idea that instrumental learning can occur subconsciously has been around for nearly a century, it had not been unequivocally demonstrated. Now, a new study published by Cell Press in the August 28 issue of the journal Neuron used sophisticated perceptual masking, computational modeling, and neuroimaging to show that instrumental learning can occur in the human brain without conscious processing of contextual cues.

The Addicted Brain May Be Protected By Cocaine-Induced Brain Plasticity
A new study has unraveled some of the mysteries of the cocaine-addicted brain and may pave the way for the design of more effective treatments for drug addiction. The research, published by Cell Press in the August 28 issue of the journal Neuron, identifies specific brain mechanisms that underlie addiction-related structural changes in the brain and provides surprising insight into how these changes may actually defend the brain during excessive drug use.


Research

Dr. Yong

Professor in the Departments of Oncology & Clinical Neurosciences, University of Calgary, AB
View BIO

 

Q :

I heard that more than just myelin is destroyed in the brain by MS and that the brain actually shrinks. Is that true and is any research taking place to try and stop it?

A :

Yes, the brain actually shrinks in MS. This is due to continuing degeneration (neuro-degeneration) of constituents within the brain as the disease progresses. These constituents include not only myelin and the oligodendrocytes that make myelin in the first place, but also nerve cells (neurons) and their fibers. The shrinkage of the brain, referred to as “brain atrophy”, can be detected by MRI scans of the brain when conducted over periods of years. At autopsy, the loss of brain tissue can be quite obvious to the naked eye.

Neuro-degeneration and brain atrophy are the major factors that account for the progress of disability in patients with MS that deteriorate neurologically. It is thus critical to prevent neuro-degeneration and brain atrophy in MS. Scientists worldwide are actively researching on the reasons for neuro-degeneration and they are beginning to understand some of the molecules that cause this. As a result, a number of medications are being tested in animal models of MS in attempts to prevent the loss of brain tissue. There are indeed many “neuro-protective agents” that seem promising in laboratory studies. Providing for neuro-protection is in fact one of the most active areas of research in MS currently.

There is evidence that the two major types of immunomodulators used in MS, glatiramer acetate (Copaxone) and interferon-betas (Avonex, Rebif and Betaseron), not only affect the immune system but that they also can confer some degree of neuro-protection. The mechanisms by which these immunomodulators provide for neuro-protection seem different, with glatiramer acetate’s action being more direct within the brain tissue, while that of the interferon-betas may be considered more indirect by preventing the entry of molecules that go into the brain to destroy that structure. Many neurologists therefore advocate the use of these immunomodulators in relapsing-remitting MS and to encourage patients to stay on their medications.

We currently have no clear evidence that the loss of brain tissue in progressive MS can be reduced. However, research is quite active in this area.
Overall, we now recognize that neuro-degeneration is very significant in MS, leading to the loss of brain tissue. Research to stop this is very active and several potential neuro- protective medications are in the pipeline.
8/31/2008 4:19:40 AM
More answers from Dr. V. Wee Yong
More answers in the category: Research

For more information related to this topic, please click Research Page
DISCLAIMER: Please be aware that this information does not necessarily represent the opinion of the MS Society of Canada, and is not intended as medical advice. For specific advice and opinion, always consult a physician.
© 2008 Multiple Sclerosis Society of Canada | www.mssociety.ca

 

http://www.msanswers.ca/QuestionView.aspx?L=2&QID=35


Repair Stem Cell Institute Says Stanford University's Stem Cell Study Confirms The Futility Of Embryonics In Human Therapy
The Repair Stem Cell Institute LLC (RSCI; http://www.RepairStemCells.org) reported that Stanford University School of Medicine's recent discovery there may be limitations to the effectiveness of human therapies derived from embryonic stem cells (ESC) because the cells injected in mice stimulated the kind of immune rejection seen with transplanted organs clearly delivers a blow to proponents of embryonic stem cell research who continue to ballyhoo the promise of ESC when in effect, as the Stanford study showed, the transplanted stem cells were dead within about seven to 10 days.

Potent Promise: Back to the Womb: Reverting adult cells to an ...
Science News - USA
Doctors would then transplant these converted cells into the afflicted organ to treat the illness, whether it’s multiple sclerosis, Parkinson’s disease, ...
See all stories on this topic

Riders lend support
Leader Post - Don Mills,ON,Canada
... is trying to raise $30000 for stem cell treatments in Costa Rica, said this was just the boost he needed to keep on fighting multiple sclerosis. ...
See all stories on this topic


Early Arthritis Symptoms | Which Joint Hurts? | What Is Arthritis? | Types of Arthritis | Arthritis Diagnosis

Arthritis is not a single condition. Arthritis comprises over 100 different diseases and conditions -- the most common are osteoarthritis, gout, rheumatoid arthritis, and fibromyalgia. Common symptoms include pain, aching, stiffness, and swelling in or around the joints. Some forms of arthritis, such as rheumatoid arthritis and lupus, can affect multiple organs and cause widespread symptoms.

Signs and Symptoms of Arthritis
There are over 100 different types of arthritis. While symptoms can vary, there are certain signs and symptoms that point to the disease. Read more...

  • Arthritis Screening Quiz
  • Fast Facts About Arthritis
  • Test Your Knowledge: Arthritis
  • 10 Things You Should Know About Arthritis

    Signs and Symptoms of Rheumatoid Arthritis

    Rheumatoid arthritis (RA) is an inflammatory type of arthritis. Recognizing the symptoms leads to an accurate diagnosis and proper treatment. Read more...
  • Rheumatoid Arthritis Screening Quiz
  • Fast Facts About Rheumatoid Arthritis
  • Test Your Knowledge: Rheumatoid Arthritis
  • 10 Things You Should Know About Rheumatoid Arthritis

    Signs and Symptoms of Osteoarthritis

    Osteoarthritis (OA) is the most common type of arthritis. Recognizing the symptoms leads to an accurate diagnosis and proper treatment. Read more...
  • Osteoarthritis Screening Quiz
  • Fast Facts About Osteoarthritis
  • Test Your Knowledge: Osteoarthritis
  • 10 Things You Should Know About Osteoarthritis
  • Friday, August 29, 2008

    Scientists transform adult cell, which could lead to cures

    Treatment

    Dr. Smyth

    Neurologist, MS Specialist
    View BIO
    http://www.msanswers.ca/ExpertBio.aspx?L=2&EID=57

    Q :

    My husband has primary MS and is considering going to the Sanoviv Clinic, have you ever heard of any successes they have had with MS? I can't seem to find anything about it on any of the MS web sites.


    A :
    I have never heard of the Sanoviv Clinic before. I looked it up on the internet and read about it. I have never heard of MS patient successes from the Sanoviv Clinic.
    Primary progressive MS is a type of MS that slowly progresses over time without relapses. People notice that they just can’t do things as well as they could one or two years earlier. There have been no medical treatments that have been shown to slow down the progression of this type of MS. However, some studies have shown that people with primary progressive MS may plateau out for years, and sometimes stabilize.
    We concentrate on treating this type of MS by treating the symptoms that a person is having. Much of those symptom management treatments involve exercise, healthy diet and looking after yourself. None of my patients have gone to the Sanoviv Clinic. I would be a little cautious about the Sanoviv clinic. Much of its claims seem to involve healthy life strategies that you may be able to adopt through less expensive means. There is no miraculous cure for MS. I have no doubt that you would feel better once you have rested there for a time, followed a healthy diet and done an exercise program. However, I think that you may be able to achieve many of those goals through exploring local physiotherapists in developing exercise programs, consulting a dietician, and resting properly. All of these lifestyle changes have been shown to help MS.
    8/29/2008 8:02:30 AM
    More answers from Dr. Penelope Smyth
    http://www.msanswers.ca/QuestionListByExpert.aspx?EID=57&L=2
    More answers in the category: Treatment
    http://www.msanswers.ca/QuestionList.aspx?CID=2&L=2

    DISCLAIMER: Please be aware that this information does not necessarily represent the opinion of the MS Society of Canada, and is not intended as medical advice. For specific advice and opinion, always consult a physician.
    © 2008 Multiple Sclerosis Society of Canada | www.mssociety.ca

    http://www.mssociety.ca

    http://www.msanswers.ca/QuestionView.aspx?L=2&QID=2164



    ‘I’m sorry, but another apology for MS sufferer Janet just isn’t ...
    Camden New Journal - London,UK
    Janet has secondary progressive MS, a particularly violent form of the disease that attacks the nervous system. Although she began to experience symptoms as ...
    http://www.thecnj.co.uk/camden/2008/082808/news082808_08.html
    MRI in Differential Diagnosis of MS
    In this case-based CME/CE newsletter, Dr. Tracy DeAngelis seeks an accurate diagnosis for a patient whose MRI suggests chronic demyelinating disease by applying updated McDonald Criteria and performing additional workups to rule out other potential causes of the MRI abnormalities.
    Source:
    Projects In Knowledge [more]
    http://broadcaster.medpagetoday.com/t?r=2&c=1989&l=15&ctl=D9DE:961584531C0AE512EEDCC8A7857BDC93

    Symptoms and Management

    Dr. Girard

    Neurologist, Hôtel-Dieu Hospital (CHUM)in Montreal, QC
    View BIO
    http://www.msanswers.ca/ExpertBio.aspx?L=2&EID=26

    Q :

    I have MS and my right arm currently feels uncomfortable and numb. Since the discomfort is mild, will it go away by itself after awhile, or do I really need to take cortisone to alleviate this symptom? I was diagnosed quite recently, and I still have some difficulty knowing when cortisone is really necessary.
    A :
    You seem to be having a mild relapse. This type of relapse will generally resolve within a few weeks. Cortisone usually helps you to recover faster when you have a relapse, but not any better than if you did not have cortisone. For that reason, we only administer cortisone for more severe relapses that affect how you function (loss of vision, paralysis, dizziness, painful numbness) to reduce their duration.

    When a neurologist decides to administer cortisone, he or she must take into account the extent of the relapse compared with cortisone’s side effects: a blood sugar level imbalance, heartburn, sleep disturbances and, subsequently, a higher risk of cataracts and hip fractures.

    In your case, it does not seem to be necessary to use cortisone.
    8/28/2008 2:12:48 AM

    More answers from Dr. Marc Girard
    http://www.msanswers.ca/QuestionListByExpert.aspx?EID=26&L=2

    More answers in the category: Symptoms and Management

    http://www.msanswers.ca/QuestionList.aspx?CID=10&L=2

    http://www.msanswers.ca/QuestionView.aspx?L=2&QID=2160
    Elan says Tysabri brain disease link uncertain
    ShareCast via Yahoo! UK & Ireland Finance Thu, 28 Aug 2008 5:16 AM PDT
    Irish drug giant Elan said the risk of a fatal brain disease in patients treated with its multiple sclerosis drug Tysabri "cannot be precisely estimated."
    http://uk.biz.yahoo.com/080828/214/i5qho.html

    Tysabri

    Elan says Tysabri brain disease link uncertain
    ShareCast - London,UK
    LONDON (SHARECAST) - Irish drug giant Elan said the risk of a fatal brain disease in patients treated with its multiple sclerosis drug Tysabri “cannot be ...
    http://www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=2301668

    Dublin market flat in early trading
    Irish Times - Dublin,Ireland
    ... up 11 cent to €9.46 after it said it had narrowed it first half loss on the back of a strong rise in sales for its multiple sclerosis drug Tysabri. ...
    http://www.irishtimes.com/newspaper/breaking/2008/0828/breaking21.htm

    Elan as Tysabri sales rise
    Irish Times - Dublin,Ireland
    Irish pharmaceutical firm Elan has narrowed it first half loss on the back of a strong rise in sales for its multiple sclerosis drug Tysabri. ...
    http://www.irishtimes.com/newspaper/breaking/2008/0828/breaking18.htm

    FDA Changes Course for Elan and Biogen Idec
    Motley Fool - USA
    Three months later, in February 2005, the drugmakers "voluntarily" withdrew Tysabri from the market because of two occurrences of a rare and frequently ...
    http://www.fool.com/investing/general/2008/08/26/fda-changes-course-for-elan-and-biogen-idec.aspx

    Biogen Idec (BIIB) NewsBite - BIIB Revises Drug Warning
    Market Intelligence Center - Charlottesville,VA,USA
    Shares of BIIB are trading higher this morning after the company announced it has revised the warning label for Tysabri, a multiple sclerosis drug the ...
    http://www.marketintelligencecenter.com/articles/665187

    Elan's shares jump 10pc on Tysabri hopes
    Irish Independent - Dublin,Ireland
    By Ailish O'Hora Business News Editor SHARES in drugmaker Elan surged by more than 10pc yesterday on hopes that a new warning on its Tysabri medicine for ...
    http://www.independent.ie/business/irish/elans-shares-jump-10pc-on-tysabri-hopes-1463799.html

    Tysabri sales narrow Elan H1 loss
    RTE.ie - Ireland
    Sales of Tysabri were worth almost $360m in the six months, almost treble the amount in the same period a year earlier, bringing in revenue of $134.3m for ...
    http://www.rte.ie/business/2008/0828/elan.html

    Elan reports total revenue increased by 18% in H1 2008; Net loss ...
    FinFacts Ireland - Ireland
    Total in-market sales of the MS (multiple sclerosis) Tysabri drug were $359.7 million in the first half of 2008, an increase of 199% over the $120.5 million ...
    http://www.finfacts.ie/irishfinancenews/article_1014558.shtml


    Exclusive: Martial arts champion hit by multiple sclerosis denied ...
    Glasgow Daily Record - Glasgow,Scotland,UK
    Alan added: "With the advances in stem cell research, there is some suggestion there could be a cure within the next five years, which gives us hope. ...
    http://www.dailyrecord.co.uk/news/scottish-news/2008/08/28/no-way-to-treat-a-hero-86908-20714087/

    Diabetes researchers convert pancreas cells to produce insulin
    http://link.latimes.com/r/ZEZWGA/MRJMH/F9K2FA/U82N/1FJEQ/W1/h

    By Karen Kaplan

    The Harvard study may ultimately shift treatment options away from stem cells for a variety of diseases.

    http://link.latimes.com/r/ZEZWGA/MRJMH/F9K2FA/U82N/1FJEQ/W1/h

    Preventive migraine therapy with a proven safety profile
    Looking for a different treatment option for migraine patients? Consider the #1 medication prescribed by neurologists for migraine prevention1. Click to learn more about a treatment option with a proven safety profile. 1.IMS Health January 2008 . Source: Ortho-McNeil Neurologics
    http://broadcaster.medpagetoday.com/t?r=2&c=1989&l=15&ctl=D9E3:961584531C0AE512EEDCC8A7857BDC93
    Obesity-Related Impairment in Older Adults Called Ticking Time Bomb
    PLYMOUTH, England -- Obesity in later life substantially increases the risk of disability but not mortality, according to data from a longitudinal study of aging. full story
    http://broadcaster.medpagetoday.com/t?r=2&c=1989&l=15&ctl=D9BF:961584531C0AE512EEDCC8A7857BDC93http://broadcaster.medpagetoday.com/t?r=2&c=1989&l=15&ctl=D9BF:961584531C0AE512EEDCC8A7857BDC93

    http://www.medpagetoday.com/PrimaryCare/Obesity/tb/10665

    Stem cell alchemy

    Researchers flip fully-differentiated cells in vivo into another type of cell without first reprogramming them to a pluripotent state

    By Andrea Gawrylewski
    http://strongmail.the-scientist.com:80/track?type=click&mailingid=867&messageid=1&databaseid=8&serial=1204298075&emailid=fooledbyasmile@mountaincable.net&userid=54355&extra=&&&2013&&&http://www.the-scientist.com/blog/display/54976/

    NOVA | scienceNOW | Stem Cell Breakthrough: Related Science News | PBS

    Thu, 31 Jul 2008 Stem Cell Advance Turns Skin Cells into Nerve Cells .... A top scientist using stem cells from human embryos to cure disease and repair ...
    www.pbs.org/wgbh/nova/sciencenow/0305/03-related.html
    http://www.pbs.org/wgbh/nova/sciencenow/0305/03-related.html


    Thu, 31 Jul 2008

    Stem Cell Advance Turns Skin Cells into Nerve Cells

    http://www.jsonline.com/story/index.aspx?id=778485

    Researchers are one step closer to reprogramming skin cells into tailor-made, healthy replacements for diseased cells.

    Applying the technique first developed by James Thomson of the University of Wisconsin-Madison and Shinya Yamanaka of Kyoto University, scientists at Harvard and Columbia universities reported online Thursday in the journal Science that they had turned skin cells from two elderly patients with the neurodegenerative disorder amyotrophic lateral sclerosis (ALS) into motor neurons, the nerve cells that become damaged in ALS, also known as Lou Gehrig's disease.

    This is the first time that scientists have coaxed embryonic-like cells from adult patients suffering from a genetic-based disease, then induced the cells to form the specific cell types that would be needed to study and treat the disease.

    http://www.pbs.org/wgbh/nova/sciencenow/0305/03-related.html

    Stem cell advance turns ailing sisters' skin cells into nerve cells

    Elderly siblings have Lou Gehrig's disease
    By ELIE DOLGIN
    edolgin@journalsentinel.com
    Posted: July 31, 2008
    Researchers are one step closer to reprogramming skin cells into tailor-made, healthy replacements for diseased cells.
    90283

    Applying the technique first developed by James Thomson of the University of Wisconsin-Madison and Shinya Yamanaka of Kyoto University, scientists at Harvard and Columbia universities reported online Thursday in the journal Science that they had turned skin cells from two elderly patients with the neurodegenerative disorder amyotrophic lateral sclerosis (ALS) into motor neurons, the nerve cells that become damaged in ALS, also known as Lou Gehrig's disease.

    This is the first time that scientists have coaxed embryonic-like cells from adult patients suffering from a genetic-based disease, then induced the cells to form the specific cell types that would be needed to study and treat the disease.

    "It's a big step forward," said Stephen Duncan, a stem cell researcher at the Medical College of Wisconsin in Wauwatosa, who was not involved in the research. "It opens the door for people to go confidently into generating (reprogrammed stem) cells for other disease models."

    "We're on the threshold of a new era of technology where we might have some definitive strategies to better treat or cure diseases like ALS or other neurodegenerative diseases," said Medical College neurologist Paul Barkhaus.

    A team led by Kevin Eggan of the Harvard Stem Cell Institute in Boston started with skin cells from two sisters, ages 82 and 89, who both carried a rare gene associated with a slowly progressing form of ALS.

    Around the world, one or two people per 100,000 develop ALS each year, which is marked by a wasting away of certain spinal cord nerve cells called motor neurons. The single-gene form of ALS studied by Eggan's team affects only about 2% of ALS sufferers, while the vast majority of ALS cases are sporadic.

    In their laboratory, the researchers inserted four genes into the cells using a virus - just as Thomson and Yamanaka had done last November - that rewound the cell's developmental clock into an embryonic-like state.

    The researchers then bathed the cells in signaling molecules to produce motor neurons and the nerve cells that support and protect the neurons, called glial cells.

    "It's possible to use these cells to make the actual cell type that is destroyed in that person's disease," Eggan said. "It takes the study of disease out of the patient, where it's very difficult, and into the petri dish."

    The researchers' ultimate goal is to create genetically matched, patient-specific cells to treat debilitating diseases. But the current technique of inserting genes with viruses has potential cancerous side effects, making transplanting these cells into humans too risky.

    "The process leads to genetic modification of these cells," Eggan said. "For the moment, that would preclude the use of these exact cells in these patients."

    Future research should find safer reprogramming methods, scientists say. In the meantime, the new reprogrammed stem cells will be valuable for understanding and combating the damage ALS does to the nervous system.

    "These patient-specific stem cells will be useful for pathological studies, and potentially also for drug screening," said UW-Madison stem cell researcher Su-Chun Zhang, who was not involved in the study.

    "Using these cells, we can test chemical compounds for their ability to prevent (neuron) degeneration," said Christopher Henderson, a neurologist at Columbia University and a co-author of the study.

    UW-Madison's Junying Yu, the first author on Thomson's pioneering reprogramming study, published last year, said the new research is a natural extension of their earlier "proof of principle" work.

    "It essentially proves that (reprogrammed stem) cells can be derived from diseased human (skin) cells as well" as from healthy patients, "at whatever age, young people or old people."

    Yu said her lab also reprogrammed skin cells from patients suffering from spinal muscular atrophy, a neurodegenerative disease that controls voluntary muscle movement.

    Like Eggan's group, Yu said her team then successfully formed the muscle cells normally lost by the disease, although the work is not yet published.

    Eggan's study shows that specialized cells can be made from skin cells in the lab, but the researchers didn't test whether the cells function in the same way as normal motor neurons, noted UW-Madison stem cell researcher Clive Svendsen.

    "The hard work now is to establish whether the ALS (reprogrammed) cells are any different from those taken from normal patients."

    Because reprogrammed stem cells can trigger cancer, scientists stress that research involving human embryonic stem cells is still needed.

    Researchers step closer to using stem cells to cure disease

    http://www.jsonline.com/story/index.aspx?id=778485

    www.kansascity.com | 08/27/2008 | Scientists transform adult cell, which could lead to cures
    ...
    http://www.kansascity.com/news/nation/story/770312.html

    27 Aug 2008 ... WASHINGTON | Scientists have transformed one type of fully developed adult ... Scientists transform adult cell, which could lead to cures ...
    www.kansascity.com/news/nation/story/770312.html

    Scientists transform adult cell, which could lead to cures

    By ROB STEIN
    The Washington Post

    WASHINGTON | Scientists have transformed one type of fully developed adult cell directly into another inside a living animal.

    It’s a startling advance that could lead to cures for a plethora of illnesses and sidestep the political and ethical quagmires that have plagued embryonic stem cell research.

    Through a series of experiments involving mice, the Harvard biologists pinpointed three crucial molecular switches that, when flipped, completely convert a common cell in the pancreas into the more precious insulin-producing ones that diabetics need to survive.

    The feat, published online Wednesday by the journal Nature, raises the tantalizing prospect that patients suffering from not only diabetes but also heart disease, strokes and many other ailments could eventually have some of their cells reprogrammed to cure their afflictions without the need for drugs, transplants or other therapies.

    “It’s kind of an extreme makeover of a cell,” said Douglas Melton, co-director of the Harvard Stem Cell Institute, who led the research. “The goal is to create cells that are missing or defective in people. It’s very exciting.”

    The findings left other researchers in a field that has become accustomed to rapid advances reaching for new superlatives to describe the potential implications.

    “I’m stunned,” said Robert Lanza, chief scientific officer of Advanced Cell Technology in Worcester, Mass., a developer of stem cell therapies. “It introduces a whole new paradigm for treating disease.”

    Melton and other researchers cautioned that many years of research lay ahead to prove whether the development would translate into cures.

    The research is the latest development in the explosive field of “regenerative medicine,” which is trying to create replacement tissues and body parts tailored to patients. That dream appeared within reach after scientists discovered human embryonic stem cells, which can develop into any type of cell in the body. But stem cell research has been plagued by political and ethical debates because the cells can only be obtained by destroying embryos, which has been opposed by President Bush and others who believe that even the earliest stages of human life have moral standing.

    The new work raises new promise.

    “This experiment proves you don’t have to go all the way back to an embryonic state,” said George Daley, a stem cell researcher at Children’s Hospital in Boston.

    http://www.kansascity.com/news/nation/story/770312.html


    Study: Single rooms should become standard for new hospitals

    http://www.uptilt.com/c.html?rtr=on&s=69l,11mca,osy,isrf,bfum,5ewk,1y5l

     

    By Anne Zieger  

    Have you noticed, lately, that when hospitals and health systems announce a new facility, it usually comes with private rooms? That's not a coincidence. Increasingly, hospital planners are reaching a consensus that the benefits to single-patient rooms far outweigh the costs, argue the authors of a new paper appearing in the Journal of the American Medical Association.


    The authors note that studies have shown single rooms to reduce infections, particularly important in the age of MRSA and other "superbugs," and that they may also cut medication errors. Also, with single rooms, physicians can talk with patients privately, and families can be there. What's more, since they're quieter, single rooms help lower patient blood pressure, heart rate and respiratory rates, as well as improving the quality of sleep and helping with pain management.

    While the authors admit that single-room hospitals increase construction costs, with added expenses of $182 to $400 per patient for a new single-room ward versus $122 to $500 for a ward with double rooms, many of these expenses are capital costs that will be recouped comparatively quickly, researchers suggest.
    To learn more about this study:
    - read this HealthDay News piece
    http://www.uptilt.com/c.html?rtr=on&s=69l,11mca,osy,1n89,m5zs,5ewk,1y5l

    Thursday, August 28, 2008

    Biogen Idec Testing Regenerative Medicine Drug to Reverse the Path of
    Multiple Sclerosis
    Luke Timmerman 8/27/08

    Biogen Idec has made a lot of its money on Avonex and Tysabri, drugs
    that slow down the rate of flare-ups for people with multiple
    sclerosis. Now the Cambridge, MA-based biotech company (NASDAQ: BIIB)
    is pursuing a loftier goal. It is working on the first experimental
    drug that may reverse the symptoms of the neurodegenerative disease.

    The drug, being tested in animals and prepped for its first human
    trial, is designed to block a protein called Lingo-1 that interferes
    with body's production of myelin, the fatty protective coating around
    nerve fibers. People with multiple sclerosis have an overactive immune
    system that eats away at the myelin layer, and they have no ability to
    regenerate myelin in the brain or spinal cord, says Sha Mi, a Biogen
    researcher. That means nerve impulses that control speech, vision, and
    movement get short-circuited, sort of like when an electrical wire is
    stripped of its insulation. Biogen thinks it now has engineered a drug
    that can stop Lingo-1 from doing its dirty work, allowing the body to
    regenerate myelin coating around nerves. That could restore normal
    functions, like walking.

    "People around the company are very excited about this," says Kenneth
    Rhodes, Biogen's vice president of discovery neurobiology. "It's
    potentially a transformational therapy." Sha Mi, the Biogen scientist
    who discovered the molecular switch that paved the way for the
    program, put it this way, "As a scientist, I came all the way from
    China. If we can create a new medicine to affect patients, that is my
    dream."

    The drug hasn't even entered clinical trials yet, and it's already
    been an eight-year odyssey. Sha Mi (who goes by the name Misha) joined
    the company in 2000 from Wyeth's Genetics Institute unit in Cambridge,
    MA. Not long after joining Biogen, she found the Lingo-1 protein in a
    database and learned it was expressed solely in the central nervous
    system and, then, only in neurons. Later experiments showed that when
    scientists delete the gene that makes Lingo-1 in mice, those altered
    mice would recover from a disease in which the immune system eats away
    at myelin, called autoimmune encephalomyelitis. The same recovery was
    seen in mice when they were given an antibody drug designed to block
    the Lingo-1 protein. There were no side effects or dangers seen from
    producing too much myelin, because the body will only produce the
    amount needed to cover nerves, Sha Mi says. The combination of
    experiments, conducted by Biogen scientists and collaborators in
    China, made the cover of Nature Medicine last October.

    Other researchers are working on myelin repair, such as a group led by
    Bruce Trapp at the Cleveland Clinic, says Rhodes, the Biogen vice
    president. Madison, NJ-based Wyeth (NYSE: WYE) has attempted to
    develop conventional small molecule drugs against Lingo, but hasn't
    been successful, he says.

    Biogen is developing a genetically engineered antibody against Lingo
    because that approach should do a better job of binding with the Lingo
    protein target on the surface of cells, Rhodes says. The first
    version, however, wasn't quite "optimal," and a newer one is being
    engineered with better properties, he says. The latest version is made
    with fully human DNA, instead of partial mouse DNA, because
    researchers want to be confident that the drug won't spark the immune
    system to reject it, especially if it needs to be given chronically.
    The company is planning to ask the FDA for permission to start its
    first human clinical trials, although he wouldn't say when.

    No details are available yet on how the trials will be crafted, but
    Rhodes made clear that the company's vision is for Lingo to be used in
    combination with Avonex or Tysabri. The idea is that those drugs can
    reduce the immune system's assault on neurons, quieting the storm.
    That would give an opportunity for the anti-Lingo-1 drug to step in
    and regenerate myelin around the nerves.

    Since 400,000 people in the U.S. suffer from MS, and there's nothing
    else quite like this program poised for clinical trials, it seems
    unlikely that Biogen will have much trouble recruiting patients in the
    first study. If they show they can regenerate myelin in even a few
    people, Biogen will be a few steps closer to fulfilling Sha Mi's dream.

    http://www.xconomy.com/boston/2008/08/27/biogen-idec-testing-regenerative-medici\
    ne-drug-to-reverse-the-path-of-multiple-sclerosis/

    Wednesday, August 27, 2008

    FDA Wants Tysabri Warning Revised

    FDA Wants Tysabri Warning Revised
    Prescribing instructions for Biogen Idec and Elan's drug Tysabri should be revised to note cases of a serious brain disorder in patients who were using it as their sole treatment for multiple sclerosis, the FDA said yesterday. The FDA said it was working to amend the Tysabri label after two cases of the brain disorder, progressive multifocal leukoencephalopathy, were reported in Europe.


    FDA Wants Biogen, Elan Drug Warning Revised
    Reuters Health - Aug. 25, 2008
    WASHINGTON (Reuters) - Prescribing instructions for Biogen Idec and Elan Corp's drug Tysabri should be revised to note cases of a serious brain disorder in patients who were using it as their sole treatment for multiple sclerosis, U.S. health regulators said on Monday.
    The Food and Drug Administration said it was working to amend the Tysabri label after two cases of the brain disorder, progressive multifocal leukoencephalopathy (PML), were reported in Europe.
    "While the two patients who developed PML were on monotherapy, the FDA still believes that Tysabri monotherapy may confer a lower risk of PML than when Tysabri is used together with other immunomodulatory medications," the FDA said in a statement on its website.
    (Reporting by Lisa Richwine; Editing by Braden Reddall)

    Related Articles:
    FDA Updates the Information for Healthcare Professionals Sheet for Tysabri (natalizumab)

    FDA seeks changes on labelling for Tysabri
    The US Food and Drug Administration has issued an alert saying it is working with Biogen Idec and Elan Corp to change the product labelling for Tysabri
    read more

    Tysabri

    Elan shares gain on positive Tysabri news
    Therapeutics Daily (subscription) (press release) - Newtown,PA,USA
    SHARES IN Irish drug developer Elan jumped yesterday following reassuring comments from the US Food and Drug Administration (FDA) and an update at a ...

    FDA Informs Doctors about Reports of Progressive Multifocal ...
    AboutLawsuits.com - Baltimore,Maryland,USA
    Both users developed PML after taking Tysabri for at least 14 months, without simultaneous use of another multiple sclerosis drug. ...

    Wednesday Newspaper Review - Irish Business News and International ...
    FinFacts Ireland - Ireland
    By Finfacts Team The Irish Independent reports that shares in drugmaker Elan surged by more than 10pc yesterday on hopes that a new warning on its Tysabri ...

    In the know: Elan, Newbury Racecourse, Taylor Nelson Sofres
    Times Online - UK
    Shares in Elan, the Irish drugmaker, rose by nearly 14 per cent, or €1.25, to €10.28 amid relief that Tysabri, its multiple sclerosis drug, ...

    Heath Winners & Losers: Biogen Idec, Elan
    TheStreet.com - USA
    Also late Monday, the FDA said it was updating the prescribing information for Biogen IdecBIIB and Elan'sELN Multiple Sclerosis (MS) drug Tysabri after two ...

    Galway meeting a success
    Irish Medical Times - Dublin,Ireland
    The latest neuroscience research into diseases including Alzheimer’s, Parkinson’s and Multiple Sclerosis were also discussed during the meeting. ...


    Biogen Idec Testing Regenerative Medicine Drug to Reverse the Path ...
    Xconomy - Cambridge,MA,USA
    Biogen Idec has made a lot of its money on Avonex and Tysabri, drugs that slow down the rate of flare-ups for people with multiple sclerosis. ...


     

    Dear Bill,

     

     

    Make your 2008-2009 Member Drive gift today.

    We are committed to a world free from multiple sclerosis. Your generous support of our 2008-2009 Member Drive is urgently needed.

    Your gift today will help us reach our goal — 1,500 new members online by midnight on September 10th.

    The National MS Society helps make sure people keep moving, despite the challenges of MS. We've changed the way MS is researched and treated — and created a wide variety of programs and services for people with MS and their families.

    We're making unprecedented progress. Our members make it all possible.

    In fact, with the generous support of people like you, the National MS Society has provided vital programs to individuals and families since 1946.

    Your member benefits will include:

    • Membership card
    • The latest news and information about MS breakthroughs
    • Biannual donor update
    • Subscription to Momentum, the magazine of the National MS Society (with a $30 gift or more to this Member Drive)
    • E-mail Newsletter

    Don't wait to help us reach our goal — support this important Member Drive today.

    I want to thank you, in advance, for your support.

    Warmly,

    Weyman T. Johnson
    Chairman, National MS Society Board of Directors
    Diagnosed in 1990

    P.S. If you've already sent your 2008-2009 Member Drive gift, thank you.

    National MS Society

    Society Store

    Forward to a Friend


    MS stops people from moving. The National MS Society exists to make sure it doesn’t.
    We are a collective of passionate individuals, moving together to create a world free of MS.
    JOIN THE MOVEMENT

    Early and ongoing treatment with an FDA-approved therapy can make a difference for people with multiple sclerosis. Learn about your options by talking to your health care professional and contacting the National MS Society at www.nationalmssociety.org or 1-800-344-4867.
    National Multiple Sclerosis Society | 733 Third Avenue | New York, NY | 10017
    This message was sent to fooledbyasmile@mountaincable.net.
    To ensure that you continue to receive our emails, please add us to your address book.

    View as Web page | Legal Notice/Privacy Policy | Unsubscribe

     

     

    We value your feedback!

    Email editor@msfocus.org
    with comments and suggestions.


    Editor's Note: The intent of this newsletter is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

    For questions regarding this publication, email editor@msfocus.org.

    For support services, email support@msfocus.org

    In This Issue

    * Tysabri Label Update

    * Clinical Trial Enrolling for Rebif Injection Device

    * Novantrone Heart Health Alert

    * Neuron Growth May Be Possible in MS Lesions

    * Study Examines Interferon Use During Pregnancy

    * Erectile Dysfunction Drugs Do Double Duty

    * 2009 Medicare Premiums Announced

    * Foods That Fight Fatigue

    * Website to Watch: Online Library of MS Research

    MSF News

    * New >From the MSF Library

    * Book Now for 2009 Cruise for a Cause

    * Caregiver’s Night Out Deadline Extended

    * Apply for a Brighter Tomorrow

    * Fall Fundraisers Will Benefit MSF


    Tysabri Label Update

    The FDA has approved changes to Tysabri package inserts following two new cases of the potentially deadly brain infection progressive multifocal leukoencephalopathy (PML) in people taking the drug in the European Union.

    The changes update Tysabri’s label to include information about the two new cases, as well as to indicate that the cases occurred in people who were taking the drug as a monotherapy. Previous cases of PML occurred in people who were taking Tysabri in combination with another immunomodulatory drug.

    Tysabri’s packaging now states that the connection between the duration of treatment and PML is unknown, but that most cases of the infection have been seen in people taking the drug for more than one year.

    Both people who were diagnosed with PML in the EU have now undergone plasma washing to remove Tysabri from their systems. No further update on their condition is available at this time.

    The FDA-approved changes also make clearer who is a candidate for Tysabri, saying that the drug generally is recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate MS therapy. Previously, the packaging indicated Tysabri was for use in people who had tried several other failed therapies. The change may assist people taking Tysabri in getting coverage of the drug from their insurance company.
    Despite the recent cases, the FDA has said it still believes there is a lower risk of PML when Tysabri is taken as a monotherapy.

    The updated prescribing information and patient medication guide for Tysabri can be viewed at www.tysabri.com.

    Clinical Trial Enrolling for Rebif Injection Device

    Those taking Rebif may be eligible to enroll in a 12-week trial of a new injection device, RebiSmart.

    RebiSmart is being tested to see if it is suitable for injection of the updated formulation of Rebif, as well as to measure any side effects or issues experienced during use.

    The device is loaded with three doses of Rebif that are administered by a battery-powered electromechanical injector triggered by pressing a button. It can be adjusted for injection depth, insertion speed, medication injection speed and the amount of time the needle stays in the skin.

    Eligible people must currently be using Rebiject to take 44 mcg doses of Rebif.

    For more information, call (888) 275-7376 or visit   http://www.clinicaltrials.gov/ct2/show/NCT00735007?term=NCT00735007&rank=1

    Novantrone Heart Health Alert

    Those treating their MS with Novatrone should be aware of recently re-issued recommendations regarding heart health from the FDA.

    Since 2005, the agency has recommended that people taking Novatrone (mitoxantrone) be evaluated for a heart condition called left ventricular ejection fraction (LVEF) both before their first treatment and prior to each subsequent infusion.

    LVEF and congestive heart failure have been associated with people whose cumulative dose of Novatrone was less than 100 mg/m2. The maximum lifetime cumulative dose for Novatrone for people with MS is 140 mg/m2, or eight to 12 doses in two to three years. 

    Those people who have finished treatment with Novatrone also should be evaluated yearly to detect cardiac problems.

    For more information on the FDA’s advisory, visit http://www.fda.gov/MedWatch/safety/2005/Novantrone_ptinfomay24.pdf

    Neuron Growth May Be Possible in MS Lesions

    Researchers at the Cleveland Clinic Lerner Research Institute found evidence that neurons may regrow in brain lesions caused by MS, although it is not clear how much function those neurons would have.

    The scientists looked at nine people with MS and four people with no known health conditions, finding that while neurons in the brain’s white matter were destroyed during the demylination process, in a small percentage of old lesions neurons in the white matter had increased by 72 percent, compared to normal brain tissue.

    The research, which scientists said may influence future MS therapies, was published in the medical journal Brain.

    Study Examines Interferon Use During Pregnancy

    A small study by Italian researchers found that other than slightly lowered birth weight, there appeared to be no negative effects for babies exposed to interferon beta in utero.

    The retrospective study looked at 38 women, including those who had never taken drugs for MS, those who had been treated with interferon beta but discontinued use before conception, and those who took interferon beta after their pregnancy began.

    Researchers examined the health of the babies through their 18th month of life, finding no developmental problems and that the lower birth weight of children who were exposed to beta interferon during pregnancy was not statistically significant.

    Much remains unknown, however, about the effect of disease-modifying drugs on a developing fetus and no MS drug has been approved for use during pregnancy. Women in the US are advised to discontinue use of DMD prior to conception; those who become pregnant while taking MS drugs may enroll in registries established to help determine any potential negative effects.

    For more information on pregnancy registries for MS drugs, visit http://www.fda.gov/womens/registries/registries.html.

    Erectile Dysfunction Drugs Do Double Duty

    Recent research has found that some drugs developed for erectile dysfunction in men may have helpful side effects, or be beneficial for women.

    In two separate studies, scientists found that men with enlarged prostates who took Cialis (tadafil) had fewer UTI symptoms, while women with sexual problems linked to antidepressant use reported improvements in their sex life after taking Viagra.

    The study, financed by Viagra-maker Pfizer, looked at 98 women who experienced at least a month of sexual troubles triggered by antidepressant use. After eight weeks, 72 percent of the women who took the drug saw improvements in arousal, sexual enjoyment and orgasm, though the women did report a higher rate of headaches and indigestion than the placebo group. Previous studies had shown Viagra did not work for women.

    The study of Cialis looked at more than 1,000 men in five countries who took either placebo or 2.5, 5, 10 or 20 mg doses of the drug daily. It found that Cialis at any dose was an improvement over placebo, helping with UTI symptoms such as urination frequency, weak urine stream and straining.

    The research will be published in an upcoming issue of The Journal of Urology.

    2009 Medicare Premiums Announced

    Premiums for Medicare Part D prescription drug plans will rise by an average of three dollars a month in 2009, an increase of about 12 percent over this year’s rates.

    Individual premiums vary by plan and location. About 24.4 million Americans are enrolled in Part D plans nationwide.

    The increase, announced by Medicare officials in August, is in part caused by the rising cost of prescription drugs. Despite the rise, the average annual costs of a Part D plan remains 37 percent lower than originally anticipated when the coverage was first conceived in 2003.

    Those who pay an additional premium will be able to cover gaps in their coverage, commonly known as the “donut hole,” through enhanced plans. People on limited incomes may be eligible to get extra assistance or have the premiums waived through the Low Income Subsidy. 

    Those enrolled in Medicare plans will receive their annual handbook, Medicare & You 2009 in October. Annual enrollment for Part D begins Nov. 15.

    For more information on your Medicare plan, visit http://www.medicare.gov or call 1-800-MEDICARE (1-800-633-4227).

    Foods That Fight Fatigue

    While no one food provides the perfect energy boost, simple steps are important to keep your body running.

    • Eat breakfast – Blending carbohydrates and protein is best, even when you are on the go. Quick breakfasts include a whole grain bagel with cream cheese or whole grain toast with peanut butter and a piece of fruit.
    • Drink water – Use water to quench your thirst, instead of sugary drinks or soda. Carry a water bottle with you during the day and treat yourself to a fruity ice-pop for desert.
    • Eat often – Three large meals a day might not be what works best for your body. Try splitting up your calories into six smaller meals for sustained energy.
    • Be wary quick fixes – Sugar and caffeine provide a rapid energy boost, followed by a crash. Caffeine in drinks also can dehydrate your body.

    For more tips, check out http://www.webmd.com/solutions/fight_fatigue.

    Website to Watch: Online Library of MS Research

    Journals, magazines, books and papers included in the United Kingdom’s Multiple Sclerosis Society library are now open to the public online.

    The collection, which is searchable, has documents for people with MS, their doctors and children. Some medical journals will allow access to full text articles; abstracts will be provided for other publications with the full article on request.

    For more information, or to search for articles, visit http://www.mssociety.org/uk/library

    MSF News

    New From the MSF Library

    The Tortoise and the Chair: Living with Multiple Sclerosis
    By Sally Rickert, Xlibris 2008

    This gem of a book is filled with poetry, first-person narratives, and short stories that address some facet of the physical or emotional fallout associated with MS. If you’ve ever adjusted to using a cane or wheelchair, have allowed the fear associated with incontinence to shrink your world, or have watched your loving partner become your primary caregiver, Sally Rickert’s deft phrases (like “dry-pants people”) will resonate with you.

    Sally previously has been featured in MSFocus. Formerly a Registered Nurse, she was diagnosed with MS in 1996. The Tortoise and the Chair is available through the MSF Lending Library. Purchase it by calling 1-888-795-4274, ext. 7876, or visiting major online booksellers.

    Book Now for 2009 Cruise for a Cause

    Have you ever wondered exactly what happens on the MSF Cruise for a Cause? Check out footage of the 2008 trip to find out more at http://www.msfocus.org/programs_cruise.php.

    The MSF’s 2009 Cruise for a Cause departs February 8, 2009 from Miami, Florida, making stops in San Juan, Puerto Rico, Charlotte Amalie, St. Thomas and Philipsburg, St. Maarten.

    The program, “MS Center at Sea: The Benefits of a Comprehensive Healthcare Team,” promises to be empowering and educational, with a multidisciplinary team of speakers from the MS Institute at Shepherd Center.

    Topics will include insurance issues, cognitive impairment and the benefits of occupational therapy for fatigue, as well as sessions on speech and swallowing, and bladder and bowel symptoms. Among our esteemed scheduled speakers are: neuropsychologist Robert Godsall, PhD; Emily Cade, a case manager specializing in vocational and disability issues for individuals with chronic illnesses; occupational therapist Melinda Hodgson; speech language pathologist Bonnie Schaude; physical therapist Candy Tefertiller; certified personal trainer Jeff Segal and nurse practitioner Tracy Walker; MSF Medical Advisor Ben Thrower and pediatrician Dr. Karen Thrower.

    Cruise rates range from $655 to $1140 per person, based on double occupancy. Taxes and gratuities as well as fuel and port charges are additional.

    For questions about the MSF Cruise for a Cause, please call our Program Development Department at 800-225-6495. To book your cabin, call Fun Cruise and Travel at 888-826-9660.

    Caregiver's Night Out Deadline Extended

    If a relative, child, partner or friend is making a difference in your life, honor them this November during National Family Caregivers Month. Nominations will be accepted until September 15 for the MSF’s 7th annual Caregiver’s Night Out contest.

    Tell us your story for a chance to win dinner for two at a restaurant of your choice. Winning essays will be published in the Fall, 2008 issue of MSFocus.

    To enter, send us your name, address, phone number and email address, along with 100 words or fewer about what makes your caregiver special.

    Email your information to homecare@msfocus.org  or download an application at http://www.msfocus.org/PDF/Caregiver_application.pdf and send it to Caregivers’ Night Out Contest, Multiple Sclerosis Foundation, 6350 N. Andrews Ave., Ft. Lauderdale, FL 33309.

    Apply for a Brighter Tomorrow

    Applications for the MSF Brighter Tomorrow Grant Program will be accepted through October 1.

    The Brighter Tomorrow Grant is a wish-based program and is not based solely on financial need. Its goal is to provide people with MS goods or services that will enhance their safety, self-sufficiency, comfort, or well-being. Previous grant recipients are ineligible.

    Requests must be for specific goods or services. Applicants provide basic personal and financial information, along with a brief essay of 100 words or less describing their need and how the grant will help them have a brighter tomorrow. Applications are confidential and are reviewed by our grant committee.

    Applications are available at http://www.msfocus.org/programs_grants_bwmg_app.php. For additional applications, call 1-888-MSFOCUS (673-6287).

    Fall Fundraisers Will Benefit MSF

    Settle into your stance and hit a long drive for the MSF this fall. Two golf fundraisers are in the works on the East Coast to raise money for the Foundation’s programs and services.

    In September, the fourth annual MS Busters Golf Tournament in Davidsonville, Maryland is scheduled for Friday, September 19 at Renditions Golf Course. Players will have a chance to win a 1999 Ferrari Spider worth $115,000 while helping the MSF.  For the third consecutive year, the tournament’s hole-in-one prize will be a car donated by http://www.b-dperformance.com/

    For more information about the MS Busters, visit

    www.ms-busters.com. To register or reserve a sponsorship opportunity for the golf tournament, call (410) 693-9302 or (301) 412-0409.

    Then, in November, MSF’s Fifth Annual PAR for the Cause Golf Tournament will take place in Florida, the “Golf Capital of the World.” Presented by Toshiba Business Solutions and scheduled for Friday, November 21 at the Woodlands Country Club in Tamarac, Florida, the Par for the Cause will start with registration at 7:45 a.m., followed by breakfast at 8 a.m. and a 9 a.m. tee time.

    To register for the Fifth Annual PAR for the Cause Golf Tournament, or for more information, call Annette Woods at (954) 776-6805 ext. 121.



    Multiple Sclerosis

    In the Spotlight | More Topics |


    from Julie Stachowiak, Ph.D.
    Okay, I'm upset. I get mail all the time from readers who say that their neurologist says that certain physical complaints couldn't possibly have anything to do with their MS. It might or it might not, but it seems that neurologists are awfully quick to dismiss things that go beyond tingling, tremor and walking difficulties. I am highlighting three things that can definitely be linked to MS, but don't automatically come to mind when one thinks of MS symptoms. Hope this helps. Take care of yourselves, my friends.


    In the Spotlight 

    Headache as a Symptom of MS
    I know that everyone gets headaches, constipation and the occasional cough. However, for those of us with multiple sclerosis (MS), these common ailments may be caused (or made worse) by our MS.

    If you are bothered by any of these problems, mention them to your neurologist. If he/she seems dismissive, stand your ground and insist on help. We already battle so many little and big problems that we need relief from anything that can be treated - and all of these can.

    Read the full article: Headaches as a Symptom of MS

    Constipation as a Symptom of MS
    While this can definitely be a symptom of MS, the things that we have to do to prevent and treat constipation are pretty much the same as everybody else: fiber, water, exercise...

    Read the full article: Constipation as a Symptom of MS


    Respiratory Problems and Coughing as a Symptom of MS
    I always wondered why my colds turned into bronchitis, characterized by coughing fits that would leave me desperately gasping for air. Now I know that I just don't cough as efficiently and have to treat these coughs quickly and seriously to get relief.

    Read the full article: Respiratory Problems and Coughing as a Symptom of MS

    More Topics


    Does Sleep Have A Core Function?
    The potential necessaryfunctions of sleep were recently discussed in an article released onAugust 25, 2008 in the open-access journal PLoS Biology.Whileit is largely publicly accepted that sleep is essential, there arestill many mysteries surrounding its function and how essential it is.

    Stem cell alchemy

    Researchers flip fully-differentiated cells in vivo into another type of cell without first reprogramming them to a pluripotent state

    By Andrea Gawrylewski

    Viruses rule the deep sea

    Viruses in the deepest ocean environments are unexpectedly strong regulators of the biosphere

    By Alla Katsnelson

    Vitamin D

    Millions of US Children are Vitamin D Deficient, Warn Researchers
    Natural News.com - Phoenix,AZ,USA
    (NaturalNews) Vitamin D deficiency is widespread among infants and toddlers, according to a study conducted by researchers from the Children's Hospital in ...

    Health Matters: Vitamin D Does a Woman's Body Good
    WCTV - Tallahassee,FL,USA
    A new study shows elderly women with lower levels of vitamin-D in their body are more at risk for hip fractures. Researchers measured vitamin-D levels and ...

    Tuesday, August 26, 2008

    FTY720

    Viral infection hope
    ChronicleLive - Newcastle upon Tyne,England,UK
    The drug, FTY720, works by trapping the immune system’s white blood cells in the lymph nodes. Scientists found that low doses of the drug actually boosted ...


    Selective Killing of Autoimmune Cells Suggests Therapy for Type 1 Diabetes
    BOSTON -- Laboratory studies of type 1 diabetes and other autoimmune diseases show that boosting levels of tumor necrosis factor or its receptor activity selectively destroys autoreactive T cells, suggesting a possible cure for the diseases, investigators here reported. full story

    http://www.medpagetoday.com/Endocrinology/Diabetes/tb/10656


    NIH - Research Matters - Protein Plays Role in Preventing Autoimmunity
    Aug 25, 2008 ... Eliminating a protein called furin from immune cells in mice can lead to development of autoimmune disease, a new study reports. ...


    Mechanism That Controls the Development of Autoimmunity
    What they discovered was that mice without furin in these cells developed systemic autoimmune... disease. This means that the immune systems of the mice



    Tysabri

    Biogen (BIIB): A 'dirt cheap' biotech bet
    BloggingStocks - USA
    "Tysabri has succeeded in the marketplace because it is a superior treatment for MS -- and the patients who use it agree, despite its high cost of $30000 ...


    FDA seeks changes on labelling for Tysabri
    The US Food and Drug Administration has issued an alert saying it is working with Biogen Idec and Elan Corp to change the product labelling for Tysabri
    read more



    FDA seeks changes on labelling for Tysabri
    26 August 2008
    The US Food and Drug Administration has issued an alert saying it is working with Biogen Idec and Elan Corp to change the product labelling for Tysabri.
    The agency’s move is unsurprising after the firms reported two new cases of the rare brain disease progressive multifocal leukoencephalopathy in Europe in patients with multiple sclerosis taking Tysabri (natalizumab) as monotherapy. The agency confirmed that these are the first cases of PML that have been reported following the drug’s re-appearance on the market in June 2006.
    However, the FDA said it "still believes that Tysabri monotherapy may confer a lower risk of PML than when Tysabri is used together with other immunomodulatory medications”. It also noted that no new cases have been seen in the USA, where about 3,300 patients have received the drug for at least one and a half years.
    Meantime, a number of private equity firms are interested in making a bid for Elan’s drug delivery unit. Bain Capital has emerged as a potential buyer for Elan Drug Technologies and Reuters has reported that Warburg Pincus may also make an offer.
    The sale of EDT is expected to bring in up to $1.4 billion for Elan, which has seen its shares collapse of late over mixed results for its Alzheimer's drug candidate bapineuzumab, being co-developed with Wyeth, as well as its Tysabri problems. Other bidders mentioned in dispatches include Texas Pacific Group, Cinven, and Kohlberg Kravis Roberts.
    By Kevin Grogan
    Latest forum comments
    "The US Food and Drug Administration has issued an alert saying it is working with Biogen Idec and E.."
    http://www.pharmatimes.com/WorldNews/article.aspx?id=14209&src=EWorldNews
    Read more and comment in the forums




    Gloucestershire pensioner has to pay for vital drugs
    Evening Post - Bristol,England,UK
    ... for those who live with them as cancer (such as – to name but a few – motor neurone disease, heart failure and primary progressive multiple sclerosis). ...


    Study Highlights Link Between Vitamin D And Multiple Sclerosis
    Medical News Today Sat, 23 Aug 2008 4:15 AM PDT
    Vitamin D, the principal regulator of calcium in the body, may prevent the production of malignant cells such as breast and prostate cancer cells and protect against specific autoimmune disorders including multiple sclerosis (MS) according to an article by Sylvia Christakos, PhD, of the UMDNJ-New Jersey Medical School.


    Study Highlights Link Between Vitamin D and Multiple Sclerosis
    Newswise Fri, 22 Aug 2008 12:31 PM PDT
    Vitamin D, the principal regulator of calcium in the body, may prevent the production of malignant cells such as breast and prostate cancer cells and protect against specific autoimmune disorders including multiple sclerosis.


    MS Answers

    Symptoms and Management

    Dr. Marrie

    Assistant Professor of Medicine and Community Health Sciences at the University of Manitoba

    View BIO

    Q :

    I am wondering if MS can cause severe joint pain, or if a person can have Lupus and MS at the same?


    A :

    Multiple sclerosis does not directly cause severe joint pain. Joint pain could occur if you develop spasticity or weakness which alters the position of the joint, or the amount of support around the joint. Strictly speaking, lupus and MS should not co-exist. Other causes of joint pain, such as rheumatoid arthritis, osteoarthritis, and gout can co-exist with MS. Talk with your GP abut this pain to rule out non-MS causes of joint pain.
    8/26/2008 6:47:51 AM
    More answers from Dr. Ruth Anne Marrie
    More answers in the category: Symptoms and Management


    DISCLAIMER:
    Please be aware that this information does not necessarily represent the opinion of the MS Society of Canada, and is not intended as medical advice. For specific advice and opinion, always consult a physician.
    © 2008 Multiple Sclerosis Society of Canada | www.mssociety.ca

    http://www.msanswers.ca/QuestionView.aspx?L=2&QID=2136

    Family Issues


    Dr. Kalb





    Dr. Kalb

    Director of the Professional Resource Center at the National Multiple Sclerosis Society in New York City, NY


    View BIO





    • Q :
    • My father has been living with MS for 10 years and is noticeably disabled. I have recently been diagnosed and I am concerned about how to explain it to my 4 year old and 2 year old. The 4 year old understands that mommy is sick, but I do not want him to associate it with how sick Papa is. How do I explain all of this to him without scaring him even more than he already is? Would it be best simply not name it for now and let them grow into the understanding when they are older that mommy and Papa have the same thing?
    • A :

      You mention that your 4-year-old knows that “mommy is sick,” but you didn’t describe what kinds of symptoms you’re having at this time. In order to help your kids understand what’s going on without scaring them unnecessarily, I would recommend the following strategies:
      • First, remember that your two children probably have very different needs at this time. Although your 4-year-old may have some questions and worries about your health, your 2-year-old may not be interested in any of this for a while yet. So I would start by talking with your older child first, and then have separate conversations with your younger one as he or she begins to ask questions or show concerns.
      • Rather than talking with your kids about being “sick,” explain any symptoms or problems you are having that they can see or that interfere with your daily activities, and describe what you are doing to try and make them better. For example, if fatigue is your primary problem, you might explain that you get very tired sometimes and need to rest more than you used to. If you’re having trouble with your vision right now, you could describe how your vision is affected and that you’re taking medication or wearing an eye patch or reading large print books until it gets better. If you’re having difficulty walking, you could explain that your leg isn’t feeling very strong right now and the cane is helping you keep your balance. By talking about specific challenges and the strategies you are using to manage them, you will limit your children’s fears and reassure them that you’re taking good care of yourself.
      • Let the kids know that you have MS like Papa, but that everyone’s MS is different. If you don’t share this information with them, you run the risk that they will hear it from someone else—and it’s always better and more reassuring for children to hear important information from mom or dad. Since all children worry when a parent becomes ills or disabled, you can also reassure them that you’ll always love and take care of them.
      • While it’s important to answer your children’s questions openly and honestly, there’s no reason to overwhelm them with too much information at any one time. Be prepared to start simply and add more detail as they grow older and their questions become more complex.
      Check out the available resources for children:
      MS Society of Canada Resources:
      Parenting with Multiple Sclerosis: How parents with MS – and their kids – adapt and get stronger.
      How to Talk about MS with Your Children This guide is a practical aid to help parents communicate better with their children about multiple sclerosis.
      Keep S'myelin, a resource for children of parents with MS, is a colourful activity book intended to help children find answers to questions about multiple sclerosis and talk with their family and friends about the changes MS can bring.
      Keep Your Balance! is a colourful publication for teens which includes basic information about MS and testimonies from teens who have a parent with MS.
      My Mommy has MS This booklet for pre-school children describes MS and its effects in an easy to understand manner.
      Benjamin: My Mum is Special This publication provides a view of MS through the eyes of a child struggling to understand his mother's mysterious and sometimes frightening illness.
      National MS Society resources:
      My Grampy Can’t Walk – a colorful storybook for young children by Vanita Oelschlager.
      • Timmy’s Journey—a DVD cartoon suitable for all ages that shares a little boy’s adventure learning about MS (available upon request from Kimberly Koch at
      kimberly.koch@nmss.org)
      8/26/2008 7:31:32 AM
      More answers from Dr. Rosalind Kalb
      More answers in the category: Family Issues


      http://www.msanswers.ca/QuestionView.aspx?L=2&QID=2146


    Newest drugs may prove out of reach Cost of potent treatments threatens to unravel health care
    The Santa Rosa Press Democrat Sun, 24 Aug 2008 4:40 AM PDT
    SEATTLE -- Sally Garcia, a 53-year-old lawyer disabled by multiple sclerosis, was torn.A new-generation medication, Copaxone, was really working for her.After two decades of being in and out of hospitals, Garcia was taking steps to work again

    .

    Let's Give Them Something to Talk About: Stem Cell Research Update ...
    jewishinstlouis.org - St. Louis,MO,USA
    ... the second line of stem cells in the world and which is involved in researching treatment for Parkinson’s disease, diabetes and multiple sclerosis (MS).


    Run, bridesmaids, run!
    Aurora Beacon News - Aurora,IL,USA
    The entry fee was waived, but donations were taken for multiple sclerosis research. "My father suffers from that condition, so it's dear to my heart," ...

    Health plans upset when employers help pay high deductibles

    By Anne Zieger
    By Anne Zieger

    High-deductible health plans have been an extremely trendy idea of late, with the assumption being that consumers would use services more cautiously if they had to pay first-dollar coverage on their own. However, some employers have been muddying the waters a bit by buying high-deductible plans, then helping employees with the deductibles through their own payouts or added insurance coverage. The combined package may be as much as 40 percent cheaper than traditional coverage, while offering comparable benefits, according to one estimate for a 40-person business based in California.

    Employers like this approach, which brokers have fostered in an effort to win their business. But lately, some health plans have raised a stink over this model, which they say can push costs up substantially by taking away employees' incentive to overuse services. In fact, some California plans are so upset that they're asking employers to sign statements saying that they won't combine high-deductible plans with some types of self-insurance. Employers who won't sign could lose coverage. "Wrap-around schemes really run the risk of destroying lower-premium health products by driving up the price or making them go away completely," says Chris Ohman, president and CEO of the California Association of Health Plans.
    To date, Blue Shield, Health Net, Kaiser Permanente and Anthem Blue Cross have sent letters to insurance brokers threatening them with termination of their contract and loss of commissions if they sell so-called "wrap-around" packages. I doubt they're the last.

    .- read this Sacramento Business Journal piece